Biocompatibility Testing for Medical Devices: A Strategic Guide for 2026

Biocompatibility testing for medical devices has fundamentally changed under ISO 10993-1:2025. The familiar endpoint matrix that automatically prescribed which tests to conduct based on device contact type and duration no longer exists. Instead, manufacturers must conduct systematic biological risk assessment to determine when biocompatibility testing is necessary, which tests are appropriate, and how to justify those decisions scientifically.

For medical device manufacturers, CROs, and regulatory affairs professionals navigating biocompatibility requirements in 2026, understanding this risk-based framework is essential for efficient product development and successful regulatory submissions.

Understanding the New Biocompatibility Testing Framework

ISO 10993-1:2025 eliminated the prescriptive testing matrix that guided biocompatibility evaluation for over 30 years. The new standard requires manufacturers to determine testing needs through systematic biological risk assessment rather than automatic application of predetermined test batteries.

The Risk-Based Approach to Testing Decisions

Under ISO 10993-1:2025, biocompatibility testing decisions follow a structured process:

Characterize the device including materials, physical properties, manufacturing processes, sterilization, and patient contact characteristics.

Identify biological hazards based on device characteristics, chemical constituents, and intended use.

Estimate biological risks using available information from material data, literature, similar devices, and post-market experience.

Determine information needs through systematic assessment of what additional data is required to adequately evaluate biological risks.

Gather existing information before planning new testing, including chemical characterization, toxicological databases, and published studies.

Conduct biocompatibility testing only when existing information is insufficient to adequately assess biological risks.

Provide scientific justification for all decisions, including decisions not to conduct specific tests.

This approach emphasizes efficient use of resources, animal welfare, and scientifically defensible safety conclusions.

When Biocompatibility Testing is Required

Biocompatibility testing is not automatic for all medical devices. ISO 10993-1:2025 requires testing only when:

Existing information is insufficient to estimate biological risks adequately based on material data, literature, or similar device experience.

Chemical characterization cannot adequately address biological endpoints. While chemical characterization with toxicological risk assessment effectively addresses systemic biological endpoints, local tissue effects typically require biological testing.

Novel materials or applications lack established biocompatibility history for the specific intended use.

Biological equivalence cannot be established to a predicate device with known biocompatibility.

Post-market data indicates previously unidentified biological hazards requiring evaluation.

The standard explicitly states that in vivo testing shall not be conducted where valid information on released constituents and degradation products has been addressed by other means and constituents have known and acceptable toxicity profiles.

Chemical Characterization vs. Biological Testing

A critical distinction in modern biocompatibility evaluation is understanding when chemical characterization can replace biological testing versus when testing remains necessary.

When Chemical Characterization Can Address Biological Risks

Systemic biological endpoints can often be adequately evaluated through chemical characterization and toxicological risk assessment:

Systemic toxicity (acute and chronic effects on organ systems)

Genotoxicity (potential for genetic material damage)

Carcinogenicity (potential for cancer development)

Reproductive and developmental toxicity (effects on fertility or fetal development)

For these endpoints, identifying and quantifying extractables and leachables, then conducting toxicological risk assessment comparing patient exposure to established toxicological thresholds, often provides more relevant safety information than biological testing.

When Biological Testing Remains Necessary

Local biological endpoints typically require biocompatibility testing even when comprehensive chemical characterization is available:

Cytotoxicity (cell viability and metabolic function at contact sites)

Sensitization (delayed hypersensitivity or allergic responses)

Irritation (local inflammatory responses)

Implantation effects (local tissue responses to physically implanted materials)

Biological testing remains necessary for local endpoints because:

• Toxicological databases for local tissue effects are limited

• Local responses depend on complex interactions between multiple compounds

• Physical device characteristics significantly impact local responses

• Synergistic or antagonistic effects cannot be reliably predicted from chemical data alone

Practical implication: Most devices requiring evaluation of both systemic and local biological endpoints will need both chemical characterization (for systemic risks) and biological testing (for local tissue effects).

Core Biocompatibility Tests and Their Applications

When biological testing is determined necessary through risk assessment, several standardized tests address different biological endpoints.

Cytotoxicity Testing (ISO 10993-5)

Cytotoxicity testing evaluates whether device materials or extracts cause cell death or metabolic dysfunction. This is typically the first biological test conducted because it screens for general cellular toxicity.

Test methods include:

• Extract testing using appropriate extraction vehicles

• Direct contact testing for solid materials

• Indirect contact testing through barriers

When required: For virtually all devices with patient contact where biological testing is necessary, as cytotoxicity provides fundamental screening for cellular-level toxicity.

Sensitization Testing (ISO 10993-10)

Sensitization testing evaluates potential for delayed hypersensitivity reactions or allergic responses to device materials or chemical constituents.

Test methods include:

• Local lymph node assay (LLNA) in mice

• Guinea pig maximization test (GPMT)

• Buehler test in guinea pigs

• In vitro alternatives (under development and validation)

When required: For devices with prolonged or repeated skin contact, or where chemical characterization identifies known sensitizers requiring confirmation of safety at observed exposure levels.

Irritation Testing (ISO 10993-10)

Irritation testing evaluates acute inflammatory responses at contact sites, including skin, ocular, or mucosal tissue irritation.

Test methods include:

• Skin irritation tests in rabbits

• Ocular irritation tests (if applicable)

• Intracutaneous reactivity tests

• In vitro alternatives for skin irritation

When required: Based on contact type and biological risk assessment. Intact skin devices may not require irritation testing if material information and chemical characterization support low irritation potential.

Systemic Toxicity Testing (ISO 10993-11)

Systemic toxicity testing evaluates whole-body effects from acute or subchronic exposure to device materials or extractables.

Test methods include:

• Acute systemic toxicity tests

• Subacute and subchronic toxicity tests for longer-term exposures

• Material-mediated pyrogenicity testing where applicable

When required: Increasingly, systemic toxicity testing is replaced by chemical characterization with toxicological risk assessment. Testing is conducted when chemical characterization is insufficient or when specific concerns about systemic effects cannot be adequately addressed through toxicological evaluation of identified constituents.

Genotoxicity Testing (ISO 10993-3)

Genotoxicity testing evaluates potential for genetic material damage that could lead to mutations or cancer.

Test methods include:

• Bacterial reverse mutation test (Ames test)

• In vitro mammalian cell tests (chromosomal aberration, micronucleus)

• In vivo tests (when in vitro results are positive or equivocal)

When required: Chemical characterization with structure-activity relationship analysis often addresses genotoxicity concerns without testing. Genotoxicity testing is conducted when chemical characterization identifies constituents of concern or when chemical characterization is incomplete.

Local Effects After Implantation Testing (ISO 10993-6)

Implantation testing evaluates local tissue responses to implanted materials or devices that breach tissue, including inflammation, tissue integration, encapsulation, and degradation over time.

Test methods include:

• Implantation studies with durations appropriate to the device's intended contact duration (from weeks to months or longer)

• Multiple implantation sites based on clinical use (subcutaneous, intramuscular, bone, or tissue-specific sites)

• Assessment of both the implant site and surrounding tissues

• Evaluation of material degradation, absorption, or persistence where applicable

When required: For implanted devices and devices that breach tissue where local tissue response over time is a critical safety consideration. The test duration should reflect the device's intended contact duration—limited, prolonged, or permanent. Chemical characterization cannot replace implantation testing for evaluating physical tissue interactions, material degradation in vivo, or local inflammatory responses.

Key consideration: ISO 10993-6:2026 emphasizes that some non-implanted devices that breach tissue (such as certain surgical instruments or temporary tissue-contacting devices) may also require evaluation of local effects after tissue contact, not just permanently implanted devices.

Test Article Preparation and Study Design

Proper test article preparation is critical for generating meaningful biocompatibility testing results.

Test Article Requirements

Representative configuration: Test articles must represent the finished device in its clinical use state, including:

• Final materials and material specifications

• Complete manufacturing processes

• Actual sterilization method and parameters

• Appropriate aging if shelf life affects biological response

Worst-case considerations: For extraction-based tests, use maximum surface area, longest contact duration, and conditions that represent or exaggerate clinical exposure.

Avoid "lab specials": Test articles that skip manufacturing steps, use alternative sterilization, or differ from commercial configuration don't represent actual patient exposure.

Extraction Conditions

For tests using device extracts, extraction conditions should simulate or exaggerate clinical use:

Extraction vehicles selected based on contact type (polar and non-polar solvents, saline, cell culture media)

Extraction temperature and duration appropriate to clinical use scenario or representing exaggerated conditions

Surface area to extraction volume ratios following ISO 10993-12 guidance

Extraction conditions must be scientifically justified and documented in the biological evaluation plan.

Scientific Justification and Documentation

ISO 10993-1:2025 requires clear scientific justification for all biocompatibility testing decisions.

Justifying Testing Decisions

For each biological endpoint, document:

Biological hazard identification: What biological effect could occur based on device characteristics?

Risk estimation: What is the likelihood and severity of that effect based on available information?

Information sources considered: What existing data (material information, literature, chemical characterization, similar devices) was evaluated?

Evaluation approach selected: Testing, chemical characterization, existing data, or combination?

Rationale: Why is the selected approach adequate to assess biological risk for this endpoint?

This documentation should appear in your biological evaluation plan and be summarized in your biological evaluation report.

Justifying Decisions Not to Test

When biological risk assessment determines that testing is not necessary for specific endpoints, clear justification is required:

Existing information adequacy: Explain what information demonstrates biological safety without testing.

Chemical characterization results: For systemic endpoints, document how toxicological risk assessment addresses the biological effect.

Material history: Reference established safe use of materials in similar applications.

Physical characteristics: Explain how device configuration or properties eliminate the biological hazard.

Strong scientific justification for decisions not to test is as important as test results themselves.

Integrating Biocompatibility Testing with Regulatory Submissions

Biocompatibility testing results must be integrated into coherent regulatory submissions that tell a complete safety story.

FDA Submission Expectations

Biological evaluation plan: Document your systematic risk assessment and testing strategy with scientific justification.

Complete test reports: Provide full reports, not just certificates, including protocols, raw or summarized data, acceptance criteria, and deviations.

Chemical characterization data: Include extractables/leachables studies and toxicological risk assessment where applicable.

Integrated conclusions: Connect device characteristics to biological hazards to evaluation activities to safety conclusions in a logical narrative.

Traceability: Demonstrate clear links between risk assessment, testing decisions, and safety conclusions.

Common Deficiencies to Avoid

Inadequate test article description: Failing to demonstrate that test articles represent finished devices.

Missing scientific justification: Not explaining why specific tests were or were not conducted.

Incomplete chemical characterization: Conducting biological testing without adequate chemical characterization for systemic endpoints.

Poor integration: Presenting test results without connecting them to biological risk assessment and overall safety conclusions.

Outdated approaches: Reflexively following the old endpoint matrix without risk-based justification.

Working with Testing Laboratories

Selecting qualified laboratories and managing testing programs effectively ensures reliable results.

Laboratory Selection Criteria

ISO 17025 accreditation: Verify laboratory quality management system meets international standards.

ASCA program participation: Where possible, select laboratories in FDA's Accreditation Scheme for Conformity Assessment.

Scope verification: Confirm laboratory accreditation covers specific ISO 10993 parts you need.

Experience with device types: Consider laboratory experience with similar devices or materials.

Communication and responsiveness: Evaluate laboratory ability to provide technical consultation and timely communication.

Managing Testing Programs

Provide complete information: Give laboratories detailed device description, materials information, intended use, and clinical contact scenarios.

Discuss test article preparation: Ensure laboratories understand how to prepare test articles representing clinical use.

Review protocols before execution: Confirm test protocols match your biological evaluation plan and regulatory strategy.

Request complete reports: Specify need for full reports with protocols, data, and detailed conclusions, not just certificates.

Maintain communication: Stay engaged throughout testing to address questions or unexpected findings promptly.

Bottom Line

Biocompatibility testing for medical devices in 2026 is driven by systematic biological risk assessment under ISO 10993-1:2025, not automatic application of testing matrices. Success requires understanding when testing is necessary versus when chemical characterization or existing information suffices, selecting appropriate tests based on biological hazards and risks, preparing representative test articles, and providing clear scientific justification for all decisions.

Manufacturers who embrace the risk-based framework—gathering existing information before testing, using chemical characterization strategically for systemic endpoints, conducting biological testing when necessary for local tissue effects, and documenting transparent scientific rationale—will achieve efficient biocompatibility evaluation that satisfies regulatory requirements while supporting patient safety.

Expert Biocompatibility Testing Strategy and Support

Determining appropriate biocompatibility testing strategies under ISO 10993-1:2025 requires specialized expertise in biological risk assessment, toxicological evaluation, and regulatory requirements.

At JL Tox Consulting, we help medical device manufacturers develop efficient, scientifically defensible biocompatibility testing strategies that meet FDA and international regulatory expectations.

Our biocompatibility testing services include:

• Testing strategy development based on systematic biological risk assessment

• Scientific justification preparation for testing decisions and alternative approaches

• Chemical characterization guidance to address systemic endpoints efficiently

• Test protocol review ensuring studies generate regulatory-acceptable data

• Laboratory selection support and CRO oversight

• Results interpretation and integration into biological evaluation reports

Contact JL Tox Consulting for expert biocompatibility testing guidance:

Email: info@JLTox.com

Phone: (877) 899-6568